Teclistamab-Cqyv
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Linvoseltamab (Lynozyfic) for multiple myeloma.
Journal: The Medical letter on drugs and therapeutics
Published: August 12, 2025
Teclistamab for relapsed or refractory multiple myeloma.
Journal: Australian prescriber
Published: March 05, 2025
FDA Approval Summary: Teclistamab-A Bispecific CD3 T-Cell Engager for Patients with Relapsed or Refractory Multiple Myeloma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 18, 2024
Teclistamab-cqyv in multiple myeloma.
Journal: European journal of haematology
Published: August 19, 2023
Teclistamab-cqyv: The First Bispecific T-Cell Engager Antibody for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma.
Journal: Journal of the advanced practitioner in oncology
Published: April 03, 2023
Pharmacological Profile of Novel Anti-cancer Drugs Approved by USFDA in 2022: A Review.
Journal: Current molecular medicine
Published: March 14, 2023
Teclistamab-cqyv.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Published: January 16, 2023
Teclistamab-cqyv (Tecvayli) for multiple myeloma.
Journal: The Medical letter on drugs and therapeutics
Published: November 17, 2022
Showing 1-10 of 10
Last Updated: 09/26/2026